Clinical Trial 39829

Chattanooga, TN 37421


Study Summary:

Migraine Headache Study

Migraine headaches are a painful problem for millions of people worldwide. Migraine attacks can be much more severe than a “bad headache” — they can leave sufferers nearly disabled and unable to function at work, home, or in social settings. Doctors don’t understand everything about what causes migraine headaches, but they’re working to research and develop new medications for preventing them.

Doctors are Testing an Investigational Product for Preventing Migraines

STOP 301 is a new clinical research study that is looking for people who suffer from migraine headaches to test an investigational drug device product. This product is a nasal spray that’s used when you have a migraine attack. (“Investigational” means this combination product isn’t yet approved for use by the public.) Doctors are studying the investigational product to learn more about whether it may be effective for treating migraine headaches. 


Qualified Participants Must:

• Be 18 to 65 years of age
• Experience at least 2 migraine headaches each month
• Do not have chronic migraine

Doctors will also check other requirements to confirm that you qualify for this study.


Qualified Participants May Receive:

All qualified volunteers will receive study medication and study-related medical care at no cost.


View Contact Phone Number


Research Site Profile

View Clinic Profile


Study is Available At:

ClinSearch
6035 Shallowford Rd. Suite 109
Chattanooga, TN 37421
View Clinic Location

 


If you would like to be contacted by the clinical trial representative and live within 50 miles of this clinic, please enter your contact information, then click 'I Am Interested In This Study'

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.